Skip to main
TXG
TXG logo

10X Genomics (TXG) Stock Forecast & Price Target

10X Genomics (TXG) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 25%
Hold 42%
Sell 0%
Strong Sell 8%

Bulls say

10x Genomics is positioned favorably in the life sciences sector due to the meaningful increase in Chromium reaction volumes, indicating a robust market despite ongoing pricing pressures. The company's consumables have outpaced instrument revenue growth, with projections suggesting a remarkable 5-19x growth in consumables per platform by 2027. This trend underscores the strong demand for 10x Genomics’s integrated solutions, enhancing the company’s long-term financial outlook.

Bears say

10x Genomics has experienced a contraction in 2024, marked by double-digit pricing pressures and flat to modestly lower volume growth, with no anticipated recovery until 2027. The company's recent earnings report revealed a significant miss in Q4 results, posting an EPS of -$0.40 compared to expectations of -$0.30, alongside a disappointing full-year revenue outlook. Furthermore, despite sector expansion since its peak in 2021, the company's stock has declined over 90%, reflecting a performance below analyst expectations.

10X Genomics (TXG) has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 25% recommend Buy, 42% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 10X Genomics (TXG) Forecast

Analysts have given 10X Genomics (TXG) a Buy based on their latest research and market trends.

According to 12 analysts, 10X Genomics (TXG) has a Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

10X Genomics (TXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.